Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thomas Bales

Physician Assistant Providence, RI Physician Assistant

NPI 1649766114 CMS profile 10448549

345 Blackstone Blvd, Providence, RI 02906

Open in the dashboard

General payments

$27,991

578 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Bales of Providence, RI is reported in the CMS Open Payments database as having received $27,991 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,373 14
2024 General $1,380 40
2023 General $3,515 89
2022 General $3,998 191
2021 General $8,725 244

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Bales
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Thomas Bales were reported at $10,373. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Thomas Bales Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $8,725 $132 $37–$438 $132
2022 $3,998 $155 $48–$522 $149
2023 $3,515 $167 $52–$557 $160
2024 $1,380 $178 $55–$600 $164
2025 $10,373 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Scientific Affairs, LLC $12,367 10 payments
  2. Alkermes, Inc. $4,664 35 payments
  3. AbbVie, Inc. $1,716 87 payments
  4. Janssen Pharmaceuticals, Inc $1,446 47 payments
  5. ITI, Inc. $1,384 60 payments
  6. Sunovion Pharmaceuticals Inc. $1,051 42 payments
  7. Vanda Pharmaceuticals Inc. $776 29 payments
  8. Neurocrine Biosciences, Inc. $754 47 payments
  9. Teva Pharmaceuticals USA, Inc. $706 58 payments
  10. Otsuka America Pharmaceutical, Inc. $695 34 payments
  11. Other $2,432 129 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $14,300 3 payments
  2. Food and Beverage $13,082 571 payments
  3. Travel and Lodging $550 2 payments
  4. Education $59 2 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $13,540 54 payments
  2. INVEGA SUSTENNA $10,481 14 payments
  3. ARISTADA Cns $4,595 32 payments
  4. ARISTADA Cns $4,595 32 payments
  5. ARISTADA INITIO $4,390 27 payments
  6. ARISTADA Cns $4,383 22 payments
  7. ARISTADA Cns $4,383 22 payments
  8. VRAYLAR $1,437 75 payments
  9. CAPLYTA $1,301 57 payments
  10. LATUDA $1,051 42 payments
  11. Other $8,200 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

422

Median for Physician Assistant: 241

Drug cost

$33,048

Median for Physician Assistant: $4,110

Branded share of claims

17.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 20 $18,786
Asenapine Maleate Generic 14 $3,208
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 41 $2,634
Clozapine Generic 12 $2,349
Fluoxetine Hcl Generic 14 $996
Aripiprazole Generic 14 $847
Lurasidone Hcl Generic 11 $740
Duloxetine Hcl Generic 21 $439
Eszopiclone Generic 12 $370
Lamotrigine Generic 19 $363

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Scientific Affairs, LLC $458
$458 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $201
$201 — —
VRAYLAR
  • AbbVie, Inc. $123
$123 — —
CAPLYTA
  • ITI, Inc. $117
$117 — —
PERSERIS
  • Indivior Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record